Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Revenue (2021 - 2025)

Krystal Biotech's Revenue history spans 4 years, with the latest figure at $107.1 million for Q4 2025.

  • For Q4 2025, Revenue rose 17.53% year-over-year to $107.1 million; the TTM value through Dec 2025 reached $389.1 million, up 33.94%, while the annual FY2025 figure was $389.1 million, 33.94% up from the prior year.
  • Revenue for Q4 2025 was $107.1 million at Krystal Biotech, up from $97.8 million in the prior quarter.
  • Across five years, Revenue topped out at $107.1 million in Q4 2025 and bottomed at -$1.5 million in Q1 2021.
  • The 4-year median for Revenue is $83.8 million (2024), against an average of $66.3 million.
  • The largest annual shift saw Revenue skyrocketed 879.91% in 2024 before it grew 16.65% in 2025.
  • A 4-year view of Revenue shows it stood at -$1.5 million in 2021, then surged by 2924.6% to $42.1 million in 2023, then soared by 116.23% to $91.1 million in 2024, then rose by 17.53% to $107.1 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Revenue are $107.1 million (Q4 2025), $97.8 million (Q3 2025), and $96.0 million (Q2 2025).